Company: EUDAW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001493152-25-011729
Chunk: 24

Company: EUDA Health Holdings Ltd
Filing Date: 2025-08-08
Form: 424B5
Chunk 24
---
 Nasdaq on the date of the Conversion Notice. Our obligation to issue and sell securities to the Investor is subject to the conditions set forth in the Note Purchase Agreement and the Convertible Note. It is possible that we will not sell US$10,000,000 principal amount, in the aggregate, of the Convertible Notes, in which case our net proceeds would be reduced. We estimate the total expenses of this offering payable by us will be approximately $20,000.

The form of Note Purchase Agreement is included as an exhibit to our Current Report on Form 6-K that we filed with the SEC in connection with the consummation of this offering. See “Where You Can Find More Information.”

Ordinary Shares issued upon conversion of the Convertible Notes may be offered for sale from time to time after the date of this prospectus by the Investor. The Investor may sell some, all or none of such Ordinary Shares. We do not know how long the Investor will hold any such Ordinary Shares before selling them, and, other than as set forth herein, we currently have no agreements, arrangements or understandings with the Investor regarding the sale or other disposition of any such Ordinary Shares. In addition, except as otherwise disclosed herein, the Investor does not have, and within the past three years has not had, any position, office or other material relationship with us.

The Investor (which includes the pledgees, donees, transferees, assignees, successors and others who later come to hold any of Ordinary Shares issued upon conversion of the Convertible Notes as a result of a transfer not involving a public sale by the Investor) may offer and sell such Ordinary Shares at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. We will not receive any of the proceeds from the offering by the Investor of any such Ordinary Shares. If any such Ordinary Shares are sold through underwriters or broker-dealers, we will not be responsible for underwriting discounts or commissions or agents’ commissions.

The Investor may use any one or more of the following methods when disposing of any such Ordinary Shares or interests therein:

1. on any other national securities exchange or U.S. inter-dealer system of a registered national securities association on which our common stock may be listed or quoted at the time of sale;

2. ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

3. one or more underwritten offerings;

|